JP2012521750A - 肝硬変及び肝線維症の治療のための方法及び組成物 - Google Patents

肝硬変及び肝線維症の治療のための方法及び組成物 Download PDF

Info

Publication number
JP2012521750A
JP2012521750A JP2012501327A JP2012501327A JP2012521750A JP 2012521750 A JP2012521750 A JP 2012521750A JP 2012501327 A JP2012501327 A JP 2012501327A JP 2012501327 A JP2012501327 A JP 2012501327A JP 2012521750 A JP2012521750 A JP 2012521750A
Authority
JP
Japan
Prior art keywords
aav
igf
liver
vector
virion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012501327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521750A5 (enExample
Inventor
アロンソ、マリア プリフィカシオン フォルテス
バルトゥエーニャ、ヘスス マリア プリエト
マティーアス ソブレバルス、ルシアノ
ペトリー、ハラルド
ヤコブス フベルトゥス ティンメルマンス、エリク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of JP2012521750A publication Critical patent/JP2012521750A/ja
Publication of JP2012521750A5 publication Critical patent/JP2012521750A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/22011—Dicistroviridae
    • C12N2770/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012501327A 2009-03-27 2010-03-26 肝硬変及び肝線維症の治療のための方法及び組成物 Pending JP2012521750A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200900846 2009-03-27
ES200900846 2009-03-27
PCT/ES2010/070184 WO2010109053A1 (es) 2009-03-27 2010-03-26 Métodos y composiciones para el tratamiento de cirrosis y fibrosis hepática

Publications (2)

Publication Number Publication Date
JP2012521750A true JP2012521750A (ja) 2012-09-20
JP2012521750A5 JP2012521750A5 (enExample) 2013-05-09

Family

ID=42269789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501327A Pending JP2012521750A (ja) 2009-03-27 2010-03-26 肝硬変及び肝線維症の治療のための方法及び組成物

Country Status (8)

Country Link
US (2) US20120093775A1 (enExample)
EP (1) EP2412387B1 (enExample)
JP (1) JP2012521750A (enExample)
CN (1) CN102448501A (enExample)
AU (1) AU2010227419A1 (enExample)
CA (1) CA2756596A1 (enExample)
MX (1) MX2011010097A (enExample)
WO (1) WO2010109053A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511127A (ja) * 2017-03-15 2020-04-16 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法
US11702676B2 (en) 2017-03-15 2023-07-18 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors for the treatment of disease
JP2024506681A (ja) * 2021-02-15 2024-02-14 バイオマリン ファーマシューティカル インコーポレイテッド ｒＡＡＶ及びｒＢＶ産生のためのトランスフェクション試薬としてのヒスチジンリッチペプチドの使用
JP2024525142A (ja) * 2021-06-11 2024-07-10 スパーク セラピューティクス インコーポレイテッド Ａａｖベクターカラム精製方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045923A1 (en) * 2009-07-10 2014-02-13 Universidad Autónoma De Barcelona Gene therapy compositions for preventing and/or treating of autoimmune diseases
WO2011154308A1 (en) * 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
WO2014012025A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
JP6649265B2 (ja) * 2013-11-26 2020-02-19 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 糖原病の処置のためのアデノ随伴ウイルスベクター
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US20180057839A1 (en) * 2014-11-26 2018-03-01 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3236984B1 (en) 2014-12-23 2020-07-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Adeno-associated virus vectors encoding modified g6pc and uses thereof
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
PE20181922A1 (es) 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
WO2019028273A1 (en) * 2017-08-02 2019-02-07 Dna2.0, Inc. Dba Atum DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US11549125B2 (en) 2017-08-09 2023-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN111135311B (zh) * 2018-11-02 2023-06-13 中国科学院分子细胞科学卓越创新中心 Ecm1在预防和/或治疗肝纤维化相关疾病中的应用
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするｒｎａ
US20230295238A1 (en) * 2020-07-23 2023-09-21 The Scripps Research Institute Insulin receptor-mediated enhancement of gene transfer
NL2033264B1 (en) * 2022-10-10 2024-04-26 Amarna Holding B V Composition and method for the production of polyomaviral vector particles
CN115656517B (zh) * 2022-10-24 2023-09-12 南方医科大学南方医院 一种用于肝硬化食管胃静脉曲张的诊断和分层的蛋白标记物及其应用
CN116555266B (zh) * 2023-06-09 2024-11-12 呈诺再生医学科技(北京)有限公司 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用
CN118430796A (zh) * 2024-07-05 2024-08-02 杭州生奥信息技术有限公司 基于血液生化指标的肝纤维化无创诊断方法和系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
WO2008137490A2 (en) * 2007-05-01 2008-11-13 Genzyme Corporation Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3688920D1 (de) 1985-07-03 1993-09-30 Genencor Int Hybride Polypeptide und Verfahren zu deren Herstellung.
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0346429B1 (en) 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
AU5603998A (en) 1996-12-18 1998-07-15 Targeted Genetics Corporation Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US20080045609A1 (en) * 2006-03-12 2008-02-21 Devore Dianna L Methods and therapeutics to facilitate liver repair
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
WO2008137490A2 (en) * 2007-05-01 2008-11-13 Genzyme Corporation Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5012010823; ＶＥＲＡ　Ｍ: 'ＬＩＶＥＲ　ＴＲＡＮＳＤＵＣＴＩＯＮ　ＷＩＴＨ　Ａ　ＳＩＭＩＡＮ　ＶＩＲＵＳ　４０　ＶＥＣＴＯＲ　ＥＮＣＯＤＩＮＧ　ＩＮＳＵＬＩＮ-ＬＩＫＥ　ＧＲＯＷＴＨ　ＦＡＣＴＯＲ　Ｉ　ＲＥＤＵＣＥＳ　ＨＥＰＡＴ' ＧＥＮＥ　ＴＨＥＲＡＰＹ Ｖ１４　Ｎ３, 200702, Ｐ２０３-２１０ *
JPN5012010824; ＳＯＢＲＥＶＡＬＳ　Ｌ: '８９：　ＴＲＥＡＴＭＥＮＴ　ＯＦ　ＥＳＴＡＢＬＩＳＨＥＤ　ＣＩＲＲＨＯＳＩＳ　ＵＳＩＮＧ　ＳＶ４０　ＶＥＣＴＯＲ　ＥＮＣＯＤＩＮＧ　ＩＮＳＵＬＩＮ-ＬＩＫＥ　ＧＲＯＷＴＨ　ＦＡＣＴＯＲ　Ｉ' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＰＡＴＯＬＯＧＹ Ｖ４８, 20080101, Ｐ　Ｓ３９, ＭＵＮＫＳＧＡＡＲＤ　ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＰＵＢＬＩＳＨＥＲＳ *
JPN5012010825; ＳＯＢＲＥＶＡＬＳ　ＬＵＣＩＡＮＯ: 'ＩＮＳＵＬＩＮ-ＬＩＫＥ　ＧＲＯＷＴＨ　ＦＡＣＴＯＲ　Ｉ　ＧＥＮＥ　ＴＲＡＮＳＦＥＲ　ＴＯ　ＣＩＲＲＨＯＴＩＣ　ＬＩＶＥＲ　ＩＮＤＵＣＥＳ　ＦＩＢＲＯＬＹＳＩＳ　ＡＮＤ　ＲＥＤＵＣＥＳ　ＦＩＢＲＯＧＥ' ＨＥＰＡＴＯＬＯＧＹ Ｖ５１　Ｎ３, 201003, Ｐ９１２-９２１ *
JPN6014036163; ＭｃＣａｒｔｙ　Ｄ．　ｅｔ　ａｌ．: Ｇｅｎｅ　Ｔｈｅｒａｐｙ Ｖｏｌ．１０, 2003, ｐｐ．２１１２-２１１８ *
JPN6014036166; ＭｃＣａｒｔｙ　Ｄ．　ｅｔ　ａｌ．: Ｇｅｎｅ　Ｔｈｅｒａｐｙ Ｖｏｌ．８, 2001, ｐｐ．１２４８-１２５４ *
JPN6014036168; ＭｃＣａｒｔｙ　Ｄ．　Ｍ．: Ｍｏｌｅｃｕｌａｒ　Ｔｈｅｒａｐｙ Ｖｏｌ．１６　Ｎｏ．１０, 2008, ｐｐ．１６４８-１６５６ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511127A (ja) * 2017-03-15 2020-04-16 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法
JP7132934B2 (ja) 2017-03-15 2022-09-07 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法
US11702676B2 (en) 2017-03-15 2023-07-18 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors for the treatment of disease
US12584147B2 (en) 2017-03-15 2026-03-24 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors for the treatment of disease
JP2024506681A (ja) * 2021-02-15 2024-02-14 バイオマリン ファーマシューティカル インコーポレイテッド ｒＡＡＶ及びｒＢＶ産生のためのトランスフェクション試薬としてのヒスチジンリッチペプチドの使用
JP2024525142A (ja) * 2021-06-11 2024-07-10 スパーク セラピューティクス インコーポレイテッド Ａａｖベクターカラム精製方法

Also Published As

Publication number Publication date
MX2011010097A (es) 2011-10-19
US20130273006A1 (en) 2013-10-17
CN102448501A (zh) 2012-05-09
WO2010109053A1 (es) 2010-09-30
US20120093775A1 (en) 2012-04-19
EP2412387B1 (en) 2014-11-19
WO2010109053A8 (es) 2011-11-17
EP2412387A1 (en) 2012-02-01
CA2756596A1 (en) 2010-09-30
AU2010227419A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
EP2412387B1 (en) Methods and compositions for the treatment of cirrhosis and liver fibrosis
MX2011010116A (es) Metodo de codificacion de video, metodo de decodificacion de video, aparato de codificacion de video y aparato de decodificacion de video.
EP3068889B1 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
CN105431170A (zh) 嵌合腺相关病毒/博卡病毒细小病毒载体
US20070087433A1 (en) Metabolically activated recombinant viral vectors and methods for their preparation and use
JP6573991B2 (ja) 血管性浮腫の治療としてのｃ１ｅｉのアデノ随伴ウイルス介在性送達
US20220372512A1 (en) Methods and aav vectors for in vivo transduction
AU2013388083A1 (en) Compositions and methods for treating spinal muscular atrophy
EP4055174A1 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
JP2021532810A (ja) 糖原病ｉｉｉの処置のためのミニｇｄｅ
US20240344084A1 (en) Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb
JP7641911B2 (ja) 新型の酵素組成物
US10391144B2 (en) Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using Apo A-I Milano gene transfer
EP3302540B1 (en) Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
CN120380156A (zh) 用aav基因治疗载体治疗心肌病
CN121263526A (zh) 耳蜗毛细胞特异性启动子及其用途
US20250082782A1 (en) Transgene cassettes designed to express the human codon-optimized gene fmr1
WO2024163335A2 (en) Pten gene therapy vectors and uses thereof
US20150191527A1 (en) Methods of treating alzheimer's disease with apo a-1 milano
WO2025006957A2 (en) Non-neutralizing aav constructs and methods of generating and using same
JP2025535083A (ja) 肺特異的遺伝子の導入が可能なアデノ随伴ウイルスベクター｛ａｄｅｎｏ－ａｓｓｏｃｉａｔｅｄ ｖｉｒｕｓ ｖｅｃｔｏｒ ｃａｐａｂｌｅ ｏｆ ｓｐｅｃｉｆｉｃ ｇｅｎｅ ｄｅｌｉｖｅｒｙ ｔｏ ｐｕｌｍｏｎａｒｙ ｂｒｏｎｃｈｉ｝
CN119331061A (zh) 靶向中枢神经系统的aav衣壳蛋白变体及其用途
CN121086028A (zh) 定向进化构建的aav衣壳变体及其用途
US20160237141A1 (en) Methods of treating alzheimer's disease with apo a-1 milano
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303